A Randomized, Double-blinded Placebo-controlled, Paralleled Designed, Investigator Sponsored Study of the Effect of the GLP-1 Receptor Agonist Liraglutide on Beta-cell Function in C-peptide Positive Type 1 Diabetic Patients

Trial Profile

A Randomized, Double-blinded Placebo-controlled, Paralleled Designed, Investigator Sponsored Study of the Effect of the GLP-1 Receptor Agonist Liraglutide on Beta-cell Function in C-peptide Positive Type 1 Diabetic Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Oct 2017 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.
    • 10 Jun 2017 Biomarkers information updated
    • 16 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top